Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer (Q38983310)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer (English)

1 reference

Europe PubMed Central

8 September 2017

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Victor J Chen

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Mark Marshall

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Ute Ohnmacht

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Scott M Hynes

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Elizabeth Kumm

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

H Bruce Diaz

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Darlene Barnard

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Farhana F Merzoug

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Lysiane Huber

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Lisa Kays

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Philip Iversen

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Beatrice Voss

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Aimee Bence Lin

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Nicolas Dickgreber

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Thomas Wehler

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Martin Sebastian

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

20 June 2014

1 reference

Europe PubMed Central

8 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

32

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

955-968

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24942404%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

https://scigraph.springernature.com/pub.10.1007/s10637-014-0114-5

0 references

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Targeting the checkpoint kinase Chk1 in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Targeting checkpoint kinase 1 in cancer therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Control of the G2/M transition

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Pemetrexed: a multitargeted antifolate

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Thymidine concentrations in serum and urine of different animal species and man

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0114-5

21 January 2018

Inhibitors of checkpoint kinases: from discovery to the clinic.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24942404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003

1 reference

https://pubmed.ncbi.nlm.nih.gov/24942404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/24942404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint

1 reference

https://pubmed.ncbi.nlm.nih.gov/24942404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24942404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38983310&oldid=1800758760"